GlassScriptPhysician profile
Karrie Sweet
NPI 1831488477
$4,729.90
in general payments reported to CMS, 2019-2025
19 companies · $1,277 in 2025
The $1,277 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $314 · 2022: $664 · 2023: $1,325 · 2024: $1,151 · 2025: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,706 · Education: $47.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,705.59 |
| Education | $47.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,349.27 | 2021-2024 | |
| Genzyme Corporation | $778.02 | 2022-2025 | |
| Janssen Biotech, INC. | $502.49 | 2021-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $404.92 | 2024-2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $295.22 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $247.15 | 2021-2024 | Entyvio |
| Medtronic, INC. | $177.94 | 2024-2025 | Interstim |
| Lilly USA, LLC | $168.03 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.65 | 2021-2024 | Xifaxan |
| Apollo Endosurgery US INC | $134.31 | 2023 | Overstitch Endoscopic Suturing System |
| Gilead Sciences, INC. | $127.57 | 2025 | Livdelzi |
| Janssen Scientific Affairs, LLC | $121.60 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $78.15 | 2024-2025 | Iqirvo |
| Orphalan INC | $57.73 | 2025 | Cuvrior |
| Pfizer INC. | $40.00 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dentsply Ih Ab | $38.45 | 2024 | Navina Rectal Catheter Set Regular |
| Celltrion USA INC. | $25.07 | 2024 | Zymfentra |
| Celgene Corporation | $19.35 | 2022 | |
| Novo Nordisk INC | $18.98 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karrie Sweet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.